Loading...
Please wait, while we are loading the content...
Similar Documents
Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series
| Content Provider | Semantic Scholar |
|---|---|
| Author | Gómez-Ibáñez, Asier Serratosa, José María Guillamón, E. Garcés, Marina Giráldez, Beatriz G. Toledo, Manuel Salas-Puig, Javier López-González, Francisco Javier Rodríguez-Uranga, Juan Castillo, A. Mauri, José Angel Camacho, Jose Lloreda López-Gomáriz, Elena Giner, Pau Torres, Nerea Palau, J. A. Escobedo Molins, Albert Villanueva, Vicente |
| Copyright Year | 2017 |
| Abstract | PURPOSE Eslicarbazepine-acetate (ESL) is a third generation antiepileptic drug licensed as adjunctive therapy in adults with focal seizures. Efficacy and safety of ESL have been established in real-life setting. However, data about outcomes in elderly patients are scarce. Primary endpoint was to evaluate outcomes of ESL in elderly patients. METHOD This was a retrospective survey that included patients >65years with focal seizures who started ESL between January 2010 and July 2012 at 12 Spanish Hospitals. ESL was prescribed individually according to real-life practice. Efficacy and safety were evaluated over 1year. These patients were included within the bigger study ESLIBASE. RESULTS We included 29 patients, most of them males (18). Mean age was 71.2 year-old and epilepsy evolution was 20 years. Eighteen were pharmacorresistant at baseline. At 12 months, the mean dose was 850mg/day, the retention rate 69%, the responder rate 62% and 24.1% were seizure-free. At 12 months, 16 patients (55.2%) had ≥1 adverse effect (AE), that led to discontinuation in 7 patients. Dizziness, nausea and ataxia were the most common AEs. The tolerability profile improved in 4/5 patients who switched from carbamazepine (CBZ) or oxcarbazepine (OXC) to ESL due to AEs. CONCLUSIONS ESL was well-tolerated and effective in elderly patients in a real-life setting over 1year, with a dose around 800mg/day. AE effects improved in most of who switched from CBZ or OXC to ESL. |
| Starting Page | 53 |
| Ending Page | 56 |
| Page Count | 4 |
| File Format | PDF HTM / HTML |
| DOI | 10.1016/j.seizure.2017.04.003 |
| Alternate Webpage(s) | https://api.elsevier.com/content/article/pii/S105913111630334X |
| Alternate Webpage(s) | https://www.sciencedirect.com/science/article/pii/S105913111630334X |
| PubMed reference number | 28419947 |
| Alternate Webpage(s) | https://doi.org/10.1016/j.seizure.2017.04.003 |
| Journal | Medline |
| Volume Number | 48 |
| Journal | Seizure |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
